Isabelle Massat

Isabelle Massat

Auto-generated profile, based on publicly available information

Isabelle Massat

Fonds de la Recherche Scientifique (FNRS), Laboratoire de Neurologie Expérimentale, Université Libre de Bruxelles, Belgium

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
ASAriadna ALBAJARA SAENZ
Ariadna ALBAJARA SAENZ
TVThomas Villemonteix
Thomas Villemonteix
IMIsabelle Massat
Isabelle Massat

7 December 2004 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
IMI Massat
I Massat
DSD Souery
D Souery
JDJ Del-Favero
J Del-Favero
MNM Nothen
M Nothen
DBD Blackwood
D Blackwood
JMJ Mendlewicz
J Mendlewicz
The available data from preclinical and pharmacological studies on the role of the C-O-methyl transferase (COMT) support the hypothesis that abnormal catecholamine transmission has been implicated in the pathogenesis of mood disorders (MD). We examined the relationship of a common functional polymorphism (Val108/158Met) in the COMT gene, which accounts for four-fold variation in enzyme activity, with ‘early-onset’ (EO) forms (less than or equal to 25 years) of MD, including patients with major depressive disorder (EO-MDD) and bipolar patients (EO-BPD), in a European multicenter case–control sample. Our sample includes 378 MDD (120 EO-MDD), 506 BPD (222 EO-BPD) and 628 controls. An association was found between the high-activity COMT Val allele, particularly the COMT Val/Val genotype and EO-MDD. These findings suggest that the COMT Val/Val genotype may be involved in EO-MDD or may be in linkage disequilibrium with a different causative polymorphism in the vicinity. The COMT gene may have complex and pleiotropic effects on susceptibility and symptomatology of neuropsychiatric disorders.

29 August 2001 in Molecular Psychiatry
Verified
Journal Article
Closed access
BLB Lerer
B Lerer
FMFabio Macciardi
Fabio Macciardi
RSR H Segman
R H Segman
RAR Adolfsson
R Adolfsson
DBD Blackwood
D Blackwood
JMJ Mendlewicz
J Mendlewicz

1 August 2011 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
DSDaniel Souery
Daniel Souery
ASAlessandro Serretti
Alessandro Serretti
Raffaella CalatiRaffaella Calati
Raffaella Calati
POPierre Oswald
Pierre Oswald
IMIsabelle Massat
Isabelle Massat
JMJulien Mendlewicz
Julien Mendlewicz
The management of treatment-resistant depression is a much debated issue. In particular, the evidence supporting the commonly suggested sequential use of antidepressants from 2 different pharmacological classes is weak. This retrospective study was undertaken to investigate whether there is a better response in nonresponders switched to a different class of antidepressants (across-class) compared with nonresponders switched to an antidepressant from the same class (within-class). Three hundred forty patients with primary major depressive disorder were recruited in the context of a European multicenter project. Subjects whose current depressive episode had failed to respond to a first antidepressant trial of adequate dose and duration were included. There was no significant difference in response or remission rates between the across-class and within-class groups after controlling for possible confounders. In depressed nonresponders to a previous antidepressant treatment, switching to a different class of antidepressants was not associated with a better response or remission rate.

21 January 2004 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
JMJulien Mendlewicz
Julien Mendlewicz
IMIsabelle Massat
Isabelle Massat
DSDaniel Souery
Daniel Souery
JDJurgen Del-Favero
Jurgen Del-Favero
LOLilijana Oruč
Lilijana Oruč
CBChristine Van Broeckhoven
Christine Van Broeckhoven

14 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IMIsabelle Massat
Isabelle Massat
HSHichem Slama
Hichem Slama
MKMartin Kavec
Martin Kavec
SLSylvie Linotte
Sylvie Linotte
AMAlison Mary
Alison Mary
Philippe PeigneuxPhilippe Peigneux
Philippe Peigneux
Attention Deficit/Hyperactivity Disorder (ADHD) is a pervasive neurodevelopmental disorder characterized by 3 clusters of age-inappropriate cardinal symptoms: inattention, hyperactivity and impulsivity. These clinical/behavioural symptoms are assumed to result from disturbances within brain systems supporting executive functions including working memory (WM), which refers to the ability to transiently store and flexibly manipulate task-relevant information. Ongoing or past medications, co-morbidity and differences in task performance are potential, independent confounds in assessing the integrity of cerebral patterns in ADHD. In the present study, we recorded WM-related cerebral activity during a memory updating N-back task using functional Magnetic Resonance Imaging (fMRI) in control children and never medicated, prepubescent children with ADHD but without comorbid symptoms. Despite similar updating performance than controls, children with ADHD exhibited decreased, below baseline WM-related activation levels in a widespread cortico-subcortical network encompassing bilateral occipital and inferior parietal areas, caudate nucleus, cerebellum and functionally connected brainstem nuclei. Distinctive functional connectivity patterns were also found in the ADHD in these regions, with a tighter coupling in the updating than in the control condition with a distributed WM-related cerebral network. Especially, cerebellum showed tighter coupling with activity in an area compatible with the brainstem red nucleus. These results in children with clinical core symptoms of ADHD but without comorbid affections and never treated with medication yield evidence for a core functional neuroanatomical network subtending WM-related processes in ADHD, which may participate to the pathophysiology and expression of clinical symptoms.